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Huntington’s disease (HD) is an autosomal neurodegenerative disease. Its manifestations is selective
degeneration of medium-sized spiny neurons (MSN) in the striatum. The speciﬁcity of the vulnerability
of these GABAergic MSNs can be explained by abnormal protein accumulation, excitotoxicity, mitochon-
drial dysfunction, and failure of trophic control, among other dysfunctions. In this study, we used in vitro
and in vivomodels of HD to study the effects of GABAergic neuron stimulation on the cellular protein deg-
radation machinery. We administered the GABAB receptor agonist, baclofen, to wild-type or mutant hun-
tingtin-expressing striatal cells (HD19 or HD43). Chymotrypsin-like proteasome activity and cell viability
were signiﬁcantly increased in the mutant huntingtin-expressing striatal cells (HD43) after GABAB recep-
tor agonist treatment. In addition, we systemically administered baclofen to a HD model containing the
entire human huntingtin gene with 128 CAG repeats (YAC128). Chymotrypsin-like proteasome activity
was signiﬁcantly increased in YAC128 transgenic mice after baclofen administration. Baclofen-injected
mutant YAC128 mice also showed signiﬁcantly reduced numbers of ubiquitin-positive neuronal intranu-
clear inclusions (NIIs) in the striatum. Baclofen markedly improved behavioral abnormalities in mutant
YAC128 mice as determined by the rotarod performance test. These data indicate that stimulation of
GABAergic neurons with the GABAB receptor agonist, baclofen, enhances ubiquitin-proteasome system
(UPS) function and cell survival in in vitro and in vivo models of HD.
 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction
Huntington’s disease (HD) is an autosomal progressive neuro-
degenerative disorder involving involuntary movements associ-
ated with selective dysfunction and degeneration of the
GABAergic medium-sized spiny neurons in the striatum [1,2]. HD
is caused by mutations in exon 1 of the huntingtin gene (>36
CAG) [3]. Mutated huntingtin forms ubiquitin-positive neuronal
intranuclear inclusions (NIIs) in the affected brain regions of HD
patients [4–6] and HD model mice [7,8]. One of the potential rea-
sons for such abnormal protein aggregation is dysfunction or
downregulation of the ubiquitin-proteasome system (UPS), whichplays major roles in the clearance of abnormal, misfolded, mutated,
and damaged proteins in eukaryotic cells [9–11]. Supporting this
model of dysfunction of the UPS, inhibited proteasome activity
has been found in the striatum, frontal cortex, cerebellum, and
substantia nigra of HD patients [12].
GABAergic neurons are characterized by their release of GABA
(c-aminobutyric acid) as a neurotransmitter. GABA is known to
act as an inhibitory neurotransmitter in the mammalian central
nervous system [13]. Synaptic inhibition by GABA can be mediated
by several types of GABA receptors in the pre- and postsynaptic
terminal [14]. Fast pre- and postsynaptic inhibition is mediated
by GABAA receptors, which are ligand-gated ion channels. Slow
pre- and postsynaptic inhibition is mediated by metabotrophic
GABAB receptors, which are composed of R1a, R1b, and R2 sub-
units. Unlike ionotrophic GABAA receptors, metabotrophic GABAB
receptors can be activated directly by GABA binding, and facilitate
postsynaptic action potential [15–17]. Once activated, presynaptic
GABAB receptors suppress neurotransmitter release by inhibiting
Ca2+ channels, while postsynaptic GABAB receptors induce slow
inhibitory postsynaptic current (sIPSC), activating G protein-
coupled inwardly rectifying K+ (GIRK) channels [18,19].
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nist, baclofen, to determine the effects of GABAergic stimulation
on striatal neuronal survival and restoration of neuronal function
in in vitro and in vivo models of HD.2. Materials and methods
2.1. Cell culture and in vitro baclofen treatment
Tet-off inducible wild type (HD19, 26 CAG repeats) and mutant
(HD43, 105 CAG repeats) striatal cells were cultured at 33 C in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM; Hyclone, Logan,
UT) supplemented with 10% fetal bovine serum (Hyclone), 2 mM
L-glutamine (Sigma, St. Louis, MO), penicillin, and streptomycin.
Expression of the huntingtin gene was induced by administration
of doxycycline (1 lg/ml) for 24 h. The selective GABAB receptor
agonist, baclofen (RS-baclofen; Tocris Cookson, Ellisville, MO),
was administered to cultured cells at the indicated concentrations.
After 24 h of administration, cell culture medium was collected for
cell viability assays. Cells were harvested and lysed in a homogeni-
zation buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100) containing the following protease and phosphatase
inhibitors: 10 lg/ml aprotinin, 25 lg/ml leupeptin, 10 lg/ml pep-
statin, 10 lg/ml phenylmethanesulfonyl ﬂuoride, 50 mM sodium
ﬂuoride, 50 mM sodium orthovanadate) for protein sample
preparation.2.2. Cell viability determination
We determined cell viability by performing a lactate dehydro-
genase (LDH) assay on the collected cell medium, as per the
manufacturer’s instructions (Roche, Mannheim, Germany). LDH
activities of control or baclofen-treated striatal cells were mea-
sured by absorbance at 490 nm.2.3. In vivo baclofen administration
In this study, we used an established HD model mouse strain, a
yeast artiﬁcial chromosome (YAC) mouse with the entire human
huntingtin gene containing 128 CAG repeats (YAC128). Wild type
(WT) and mutant (MT) male YAC128 mice at 13–18 months of
age were used in this experiment. To study the effect of GABAB
receptor stimulation in vivo, mice received intraperitoneal (i.p.)
injections of baclofen (dissolved in 0.2 N NaOH) at a dosage of
10 lg/g body weight, twice daily at 9:00 a.m. and 5:00 p.m., for
3 consecutive days. Mice then received single treatments on the
fourth day at 9:00 a.m., as previously described [20]. The striatum
and frontal cortex tissues were collected 5 h after the last injection,
and frozen until used for protein preparation.2.4. Behavioral assessment
Approximately 16 h before the ﬁrst injection and 4 h after the
last injection, the mice were assessed via the rotarod test and open
ﬁeld test as previously described [21]. For the rotarod test, each
mouse was placed on a ﬁxed-speed rotarod (Panlab, Barcelona,
Spain) at a speed of 4 rpm for a maximum time of 60 s. The latency
to fall was recorded for each mouse with four trials spaced 20 min
apart in a single session. The open ﬁeld test was performed by plac-
ing each mouse in the center of an open-ﬁeld arena (30  30 cm)
with a light gray bottom subdivided by black lines into 6  6 cm
squares. The 12 min session consisted of 4 min blocks, and the fol-
lowing activities of mice in the open ﬁeld were counted during
each block: ‘crossings’ (the number of crossings of the black lineswith both forelimbs), and ‘wall-rearing’ (standing on hindlimbs
and touching the wall of apparatus with forelimb) [22].2.5. Immunohistochemistry
Perfused mouse brain tissues were cryoprotected and cut into
30 lm sections using a Thermo microtome (Thermo 430/Thermo
Fisher Scientiﬁc, Walldorf, Germany). Immunostaining of brain
sections was performed using primary antibodies against ubiqui-
tin (1:2,000; Chemicon, Temecula, CA), followed by incubation
with secondary horseradish peroxidase (HRP)-linked anti-rabbit
(1:500; Jackson Laboratories, Bar Harbor, ME) or anti-mouse
(1:500; Vector Laboratories, Burlingame, CA) IgG antibodies. After
mounting of sections onto aminosilane-coated slides, images were
obtained using a Leica ﬂuorescence microscope (DMIL/DFC295/
Leica, Bannockburn, IL).2.6. Counting of NIIs
The number of ubiquitin-positive NIIs was counted from
microscope images of three different areas of striatum in coronal
sections that were subjected to the immunohistochemical proce-
dures described above. Analysis was performed blindly by two
different assessors.2.7. Protein sample preparation and Western blot
Protein samples were puriﬁed from harvested cells and animal
tissues in homogenization buffer. Lysates were centrifuged at
13,200 rpm for 30 min at 4 C. The supernatants were collected
and stored at 80 C until use.
Cell and tissue samples containing equal amounts of total
protein were analyzed by Western blot using monoclonal anti-
huntingtin (1:1250; Abcam, Cambridge, UK), or polyclonal anti-
proteasome b-subunit (1:5000; Calbiochem, La Jolla, CA) primary
antibodies, and secondary horseradish peroxidase (HRP)-linked
anti-rabbit (1:2500; Jackson Laboratories, Bar Harbor, ME) and
anti-mouse (1:2500; Vector Laboratories, Burlingame, CA) IgG
antibodies. Quantiﬁcation of immunoreactive bands was per-
formed by quantitative densitometry. The results were conﬁrmed
by triplicate measurements of the same sample.2.8. Proteasome activity determination
Proteasome activity was determined by measuring the ﬂuores-
cence of 7-amido-4-methylcoumarin (AMC; excitation 380 nm,
emission 460 nm) generated from peptide-AMC linked substrates.
Reactions were conducted in a ﬁnal volume of 200 ll of buffer
including 50 mM Tris–HCl (pH 7.5) and 1 mM EDTA. After adding
samples to the reaction mixtures, reactions were initiated by add-
ing the substrate Suc-Leu-Leu-Val-Try-AMC (65 lM) to measure
chymotrypsin-like activity. Reactions progressed for 360 min at
25 C. Enzymatic activity was expressed as ﬂuorescence units
(FU)/mg/min of protein.2.9. Statistical analysis
All statistical analyses were performed using the SPSS software
package (version 12.0.1; SPSS Inc., Chicago, IL). Data were objec-
tively compared between different groups of cells or mice using
the independent-samples T-test. Differences between groups were
considered statistically signiﬁcant when the p value was less than
0.05.
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3.1. Baclofen enhances chymotrypsin-like proteasome activity and cell
viability in HD model cells
To address the effect of GABAergic stimulation on proteasome
activity in HD, we measured chymotrypsin-like proteasome activ-
ity in HD model striatal cells, HD19 (26 CAG repeats) and HD43
(105 CAG repeats), after baclofen treatment. HD43 cells showed a
signiﬁcant increase in chymotrypsin-like proteasome activity at
10 lM of baclofen, whereas HD19 cells did not exhibit signiﬁcant
changes (Fig. 1A). To determine whether GABAergic stimulation also
increases the viability of HD model cells, we measured LDH activity
as an indicator of cell viability. As shown in Fig. 1B, the culture
media from HD43 cells had markedly decreased LDH activity, indi-
cating increased cell viability, after treatment with baclofen at 1 or
10 lM. These data indicate that stimulation of GABAergic neurons
with a speciﬁc GABAB receptor agonist can increase chymotrypsin-
like proteasome activity and cell survival in mutant HD model cells.
3.2. Baclofen increases proteasome activity and reduces NIIs in YAC128
HD transgenic mice
To verify whether the improvements in proteasome activity and
cell survival also occur in vivo, we administered 10 lg of baclofen
per gram of body weight to YAC128 HD transgenic mice. Chymo-
trypsin-like proteasome activity decreased in the striatum of mu-
tant type (MT) YAC128 mice compared to wild type (WT)
littermates. This decreased proteasome activity in the striatum of
mutant YAC128 mice is also seen in human HD patients [12] and
mutant YAC72 mice [23]. Corresponding to the in vitro data,
chymotrypsin-like proteasome activity signiﬁcantly increased in60
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Fig. 1. The effect of baclofen on proteasome activity and cell viability in an in vitro HD
mutant (HD43, 105 CAG repeats) striatal neurons at a baclofen concentration of 10 lM. (
assay. HD43 cells showed a signiﬁcant increase of cell viability following 1 lM and 10 lthe striatum of MT YAC128 mice after baclofen administration
(Fig. 2A). In addition, the expression level of the 20S proteasome
b-subunit signiﬁcantly increased in the striatum of both WT and
MT YAC128 mice after baclofen administration (Fig. 2B).
Next, to conﬁrm whether the increased proteasome activity
effectively degrades polyglutamine aggregates in the affected re-
gion of the brain, we counted the number of ubiquitin-positive NIIs
in the striatum of WT and MT YAC128 mice after baclofen admin-
istration, by immunohistochemical analysis. As shown in Fig. 2C,
ubiquitin-positive NIIs were detected in the striatum of WT and
MT YAC128 mice after baclofen administration. Statistical analysis
of the number of NIIs indicated that baclofen-injected mutant
YAC128 mice showed signiﬁcantly reduced NIIs formation com-
pared to vehicle-injected mutant YAC128 mice (Fig. 2C). These data
suggest that GABAergic stimulation ameliorates pathological
symptoms of HD by diminishing NIIs in the striatum.
3.3. Baclofen ameliorates motor deﬁcits in YAC128 HD transgenic mice
Finally, we assessed whether behavioral abnormalities in
YAC128 HD mice are improved by baclofen administration. Com-
pared to WT littermates, MT YAC128 mice showed signiﬁcantly re-
duced latency to fall (Fig. 3) in the rotarod test and number of
crossing in open-ﬁeld test, as had been observed in a previous
study [7]. There were no differences in the number of wall-rearing
episodes between WT and MT YAC128 mice. Baclofen administra-
tion signiﬁcantly increased the latency to fall in the rotarod test in
mutant YAC128 mice (Fig. 3), Total locomotor counts of crossing
and frequency of wall-rearing episodes were not signiﬁcantly al-
tered in MT YAC128 mice after baclofen administration (Fig. 3).
These data demonstrate that the GABAB receptor agonist restored
motor coordination in YAC128 HD mice.60
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model. (A) Chymotrypsin-like proteasome activity was signiﬁcantly increased in
B) Cell viabilities of baclofen-treated HD19 and HD43 cells were determined by LDH
M baclofen treatment (⁄p < 0.05).
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Fig. 2. The effect of baclofen on proteasome activity and inclusion bodies in the striatum of YAC128 HD transgenic mice. (A) Mutant (MT) YAC128 mice showed signiﬁcantly
decreased chymotrypsin-like proteasome activity in the striatum compared to wild type (WT) littermates. Chymotrypsin-like proteasome activity was signiﬁcantly increased
in the striatum of MT YAC128 mice following baclofen administration. (B) The expression levels of the 20S proteasome b-subunit signiﬁcantly increased in the striatum of
both WT and MT YAC128 mice (⁄p < 0.05, ⁄⁄p < 0.01). (C) Ubiquitin positive NIIs were detected by immunohistochemistry using anti-ubiquitin antibody, in the striatum of WT
or MT YAC128 mice after baclofen administration. The number of ubiquitin-positive NIIs was signiﬁcantly reduced in the striatum of baclofen-injected mutant YAC128 mice,
compared to vehicle-injected group (⁄p < 0.05 within wild type or mutant group, §p < 0.05 between wild type and mutant groups). Scale bar indicates 50 lm.
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4.1. GABA and GABAB receptor expression in HD
A hallmark of HD is selective cell death of the GABAergic med-
ium-sized spiny neurons in the striatum. The ubiquitin-positive
nuclear inclusion bodies of mutant huntingtin observed in the
affected brain regions of HD patients are due to downregulation
of UPS function. In this study we aimed to enhance GABAergic
neuronal activation and proteasome function to overcome HD
pathogenesis.The expression levels of GABAB receptors are not altered in the
affected brain regions in HD model rodents [24–26], but GABA
immunoreactivity is markedly reduced in the striatum of quino-
linic acid (QA)-induced HD model rats [27]. High-resolution magic
angle spinning (HR-MAS) 1H nuclear magnetic resonance (NMR)
spectroscopy revealed that GABA concentrations are markedly re-
duced in the striatum and cerebellum of the R6/2 transgenic mouse
model of HD [28]. In human HD patients, cerebrospinal ﬂuid (CSF)
GABA levels are quite low [29]. Baclofen, a speciﬁc GABAB receptor
agonist, mimics the action of GABA and produces slow presynaptic
inhibition through the GABAB receptor [30–32]. Owing to this
710 W. Kim, H. Seo / Biochemical and Biophysical Research Communications 443 (2014) 706–711effect of presynaptic inhibition, baclofen is employed in diseases
that are accompanied by spasm or convulsion. Intraperitoneal
injection of baclofen reduced audiogenic seizures in fragile X men-
tal retardation protein (FMR1) knockout mice [33]. Intrathecal bac-
lofen treatment results in improvement of dystonia of the hands in
human patients with reﬂex sympathetic dystonia [34]. Accord-
ingly, in this study we hypothesized that functional activation of
GABAB receptors by baclofen could stimulate GABAergic med-
ium-sized spiny neurons, and ameliorate the involuntary and
uncoordinated behavioral pathology of HD.
4.2. The effect of baclofen on regulation of proteasome activity and NIIs
formation
To determine whether functional stimulation of GABAergic
MSNs through GABAB receptor activation alters ubiquitin-protea-
some system function, we measured proteasome activities and
the protein levels of the proteasome core 20S unit from WT and
MT YAC128 mice after baclofen administration. YAC128 HD trans-
genic mice exhibit selective loss of MSNs in the striatum at
9 months of age [7]. In the current study, chymotrypsin-like activ-
ity decreased in the striatum of MT YAC128 mice, similar to previ-
ous reports of human HD patients and MT YAC72 HD model mice
[12,23]. Baclofen administration increased chymotrypsin-like
activity and the survival of MSNs in the striatum of MT YAC128
mice.
Previous studies have reported that NIIs formation in polygluta-
mine diseases is closely related to reduced proteasome activity
[35–37] and that ubiquitin-positive NIIs result in apoptotic cell
death in mutant huntingtin-transfected neuroblastoma [38]. In
the current study, we determined that baclofen signiﬁcantly de-
creased NIIs formation in the striatum of YAC128 mice. This result
suggests that GABAB receptor activation effectively improves pro-
teasome function, and thus signiﬁcantly reduces pathological NIIs
in the striatum of HD model mice.
4.3. The effect of baclofen on motor coordination of mutant YAC128
mice
Motor dysfunction of mutant YAC128 mice correlating with
striatal neuronal loss begins at 6 months of age, as determined
by ﬁxed speed rotarod performance [7]. The latency to fall of
mutant YAC128 mice signiﬁcantly increased after baclofen
administration. In an open ﬁeld test, MT YAC128 mice exhibited
decreased activity of locomotion compared to WT littermates, as
previously reported [7,39]. In this study, baclofen administration
showed tendency to decrease the locomotive activities of crossing
and wall-rearing in MT YAC128 mice. These data suggest that a
speciﬁc GABAB receptor agonist can improve behavioral abnormal-
ities associated with motor coordination.
In summary, functional GABAergic stimulation via a GABAB
receptor enhances survival of striatal cells and proteasome activity
in vitro, reduces ubiquitin-positive NIIs, and consequently induces
restoration of motor function in in vivomodels of HD. Our data sug-
gest that GABAB receptor agonists could be promising therapeutic
reagents for the treatment of HD.Conﬂict of interest statement
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